Type Ii Anti-cd20 Antibody And Anti-cd20/cd3 Bispecific Antibody For Treatment Of Cancer


The full document isn't yet available to us from the patent office.


The present invention relates to combination treatment methods of treating a disease comprising a type II anti-CD20 antibody and an anti-CD20/anti-CD3 bispecific antibody. The present invention further relates to methods for reduction of cytokine release associated with the administration of a T-cell activating therapeutic agent.


Information currently unavailable.

Download Citation

Sign in to the Lens